-
ILCA 2023 | Liquid Biopsy Technology Based on Methylated SEPT9 Has the Potential to Establish a New Early Diagnosis System for Liver Cancer
Liver cancer is one of the malignant tumors with a high incidence and mortality rate in China. Most patients are clinically diagnosed late, with a high rate of postoperative recurrence and metastasis, which has become a significant factor affecting patient prognosis. There is an urgent need for technology that can effectively detect early liver cancer,…
-
ILCA 2023 | Dynamic Changes in Circulating Tumor DNA Assist in Guiding and Evaluating Clinical Treatment of Liver Cancer
Circulating tumor DNA (ctDNA) refers to free tumor DNA fragments located in peripheral circulation. These free nucleic acids not only provide a comprehensive view of tumor genetics but also indirectly reflect tumor progression, heterogeneity, and invasive ability. They represent a promising non-invasive biomarker in cancer treatment. Dr. Claudia Campani from the University of Paris delivered…
-
Dr. Tim Greten: Looking forward to Immunotherapy 4.0 era of Hepatocellular Carcinoma
Primary hepatocellular carcinoma is one of the most common malignant tumors in China, ranking second in the mortality rate of malignant tumors in the country. In recent years, significant progress has been made in HCC immunotherapy, bringing new hope to countless HCC patients. The evolution of HCC immunotherapy has gone through the era of PD-1/PD-L1…
-
ILCA 2023 | Liquid Biopsy Technology Based on Methylated SEPT9 Has the Potential to Establish a New Early Diagnosis System for Liver Cancer
Liver cancer is one of the malignant tumors with a high incidence and mortality rate in China. Most patients are clinically diagnosed late, with a high rate of postoperative recurrence and metastasis, which has become a significant factor affecting patient prognosis. There is an urgent need for technology that can effectively detect early liver cancer,…
-
ILCA 2023 | When HIV Infection Coexists with HCC: Patient Clinical Features, Treatment Status, and Outcomes
After the HIV virus enters the human body, it first destroys the immune system, leading to a rapid decline in immunity. Consequently, the body becomes more susceptible to various infections and complications, the most common of which are infections in different systems and malignant tumors. As the life expectancy of people living with HIV (PLWH)…
-
Dr. Qiang Gao: The Complexity and Diversity of Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) refers to adenocarcinoma originating from the epithelium of secondary bile ducts and their branches, accounting for 10%-15% of primary malignant tumors in the liver. In recent years, the incidence of ICC has been rising significantly, garnering increasing clinical attention. While ICC and hepatocellular carcinoma (HCC) both belong to primary liver cancers, they…
-
ESMO China Voice | Professor Long Shichun: Targeted Immunotherapy Offers Hope for Curative Resection and Long-Term Survival in Unresectable Liver Cancer
Due to the insidious nature of liver cancer, most patients are diagnosed in the advanced stages, losing the opportunity for curative surgery and facing a poor prognosis. In recent years,…
-
ESMO 2023: Advancements in Oncology, Honoring Excellence, and the Global Impact
The European Society for Medical Oncology (ESMO) 2023 Congress held in Madrid was a momentous event that brought together oncology professionals and researchers from across the globe. This comprehensive article…
Connecting Medical Expertise through Media